Medication info
Glotin Duo Tablet 2.5/500 mg (Linagliptin, Metformin Hydrochloride)

Glotin Duo Tablet 2.5/500 mg (Linagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Nexpam Korea Co., Ltd.
Appearance
Bright yellow, oval, biconvex film-coated tablet
Packaging
30 tablets/box [(6 tablets/PTP x 5 pieces)]
Approval status
Active

MFDS item code 202001274 · Approved 2020.02.21 · Insurance code 662504550

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dosage of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be taken twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug therapy whose blood glucose is inadequately controlled with monotherapy, the initial dosage of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should initially take the same doses of linagliptin and metformin they were previously taking. 3. Patients with inadequate blood glucose control on combination therapy with insulin and metformin: The initial dosage of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in Whom This Medicine Must Not Be Used).

Ingredients

Manufacturer
Nexpam Korea Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication effectively aids in blood glucose control when used together with dietary and exercise therapy in patients with type 2 diabetes. The combination of Linagliptin and Metformin stabilizes blood glucose levels and demonstrates positive effects on diabetes management. Therefore, taking this medication alongside dietary regulation and exercise management is useful for improving blood glucose control.

How to take

Adult dose

The dosage of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be taken twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug therapy whose blood glucose is inadequately controlled with monotherapy, the initial dosage of this medicine is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should initially take the same doses of linagliptin and metformin they were previously taking. 3. Patients with inadequate blood glucose control on combination therapy with insulin and metformin: The initial dosage of this medicine should be considered to be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's existing metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in Whom This Medicine Must Not Be Used).

Precautions

This medication can cause a rare but serious side effect known as lactic acidosis; thus, it should not be used in patients with impaired kidney function or severe liver disease. Additionally, patients with allergies to any of the components of this medication, individuals with type 1 diabetes, and pregnant or breastfeeding women should avoid its use. When used in conjunction with other blood glucose-lowering medications, monitoring for hypoglycemia is necessary, especially when combined with insulin or sulfonylureas which may require dosage adjustments. Elderly patients with reduced kidney function or those taking medications that may affect kidney function should undergo regular kidney function tests. In cases of acute illness or impending surgery, this medication should be temporarily discontinued. If symptoms such as acute pancreatitis or blistering skin eruptions like bullous pemphigoid occur, consult a physician immediately. This medication may cause vitamin B12 deficiency due to its metformin component, so it's recommended to regularly check vitamin B12 levels during long-term use. Avoid use during pregnancy, and it's advisable to consult a doctor about considering alternative treatments if planning to conceive or already pregnant. This product is not recommended for children under 10 years of age or adolescents aged 10 to 17, as safety and efficacy have not been established. Using this medication along with alcohol increases the risk of lactic acidosis, so alcohol consumption should be avoided. There is a possibility of drug interactions, so if other medications are being taken, it's essential to inform a physician or pharmacist, particularly when using drugs that may affect kidney function.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • vitamin B12 decrease and deficiency
  • hypoglycemia
  • taste disorder
  • cough
  • reduced appetite
Show 113 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • blistering similar to pemphigus
  • severe and debilitating arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • epigastric pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuritis
  • sepsis
  • pneumonia
  • reduced appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial swelling
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage kidney disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • pneumonia
  • hypertension
  • anxiety
  • depression
  • bruising
  • bone bruise
  • concussion
  • bone fracture
  • hand fracture
  • diabetic neuropathy
  • headache
  • drowsiness
  • itching
  • insomnia
  • benign prostatic hyperplasia
  • angina
  • acute myocardial infarction
  • unstable angina
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyps
  • dyspepsia
  • anal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • dizziness
  • inadequate control of diabetes
  • asthenia
  • pain
  • nosebleed
  • oropharyngeal pain
  • vocal disturbance
  • epistaxis
  • hearing loss
  • erectile dysfunction
  • goiter
  • confusion state
  • nocturia
  • dermatitis
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius. Proper storage will help preserve the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

Bright yellow, oval, biconvex film-coated tablet

Package unit

30 tablets/box [(6 tablets/PTP x 5 pieces)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.